Clinical Trials

Is your family from India, Pakistan, Bangladesh, Nepal, or Sri Lanka? If so, you may be able to participate in a clinical study looking at cardiovascular disease, such as heart disease and stroke among people of South Asian descent. Participants must be between 40 and 84 years old and have no history of heart attack or stroke, heart failure, angina, or atrial fibrillation. This study is taking place in San Francisco, California, Chicago, Illinois, and New York City, New York.

The goal of this work is to develop and test a noninvasive ultrasound-based imaging technology to better identify patients at high risk of stroke so that appropriate and timely intervention may be administered to prevent it.

Are you at least 40 years old and living with HIV? In this study, researchers are looking at how effective educational text messages are in reducing cardiovascular risk among persons living with HIV. You may be able to participate if you do not currently have atherosclerosis, which is the buildup of fats and cholesterol on your artery walls. The study is taking place in San Francisco, California.

Are you an adult with carotid artery stenosis (CAS)? Researchers in this study want to learn more about the plaque that causes atherosclerosis in patients with carotid artery stenosis. To be in the study, you must be at least 18 years old and will undergo a carotid positron emission tomography (PET)/magnetic resonance imaging exam so researchers can lean more on the new PET imaging approach for risk prediction in these patients. The study is taking place Saint Louis, Missouri, and in Los Angeles, California.

Are you planning to have coronary artery bypass grafting (CABG) surgery to treat your heart disease? This study aims to use computed tomography (CT) imaging to help doctors and their patients make better decisions about heart surgery. To participate in this study, you must be at least 40 years old and be scheduled for a CABG. This study is located in Palo Alto and San Diego, California

Do you have heart disease that requires an ICD to prevent sudden cardiac arrest? This study aims to learn what signs distinguish patients who have a higher risk of an arrhythmia that leads to sudden cardiac arrest. Researchers plan to track patients with a recent ICD replacement for 10 years. To participate in this study, you must be between 18 and 85 years old. This study is located in Washington, D.C.; Baltimore, Maryland; and Richmond, Virginia.

his trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice.

Sickle Cell Disease (SCD) impairs oxygen transport to tissue and causes endothelial injury. Thus, therapeutic interventions aim to improve both, but there is an unmet need for biomarkers to determine when intervention is necessary and evaluate the effectiveness of the chosen intervention in individual patients. This study proposes to monitor SCD and its treatment through their impact on cerebral hemodynamics, as the brain is one of the most vulnerable and consequential targets of the disease. Specifically, this study will optimize quantitative magnetic resonance imaging (MRI) and advanced optical spectroscopy techniques such as frequency-domain near-infrared and diffuse correlation spectroscopies (FDNIRS-DCS) to monitor 1) cerebral oxygen transport with measures of cerebral blood flow (CBF), cerebral oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen consumption (CMRO2) and 2) endothelial function with cerebrovascular reactivity (CVR).

Do you or your child have sickle cell disease? Researchers are testing whether a type of gene therapy will prevent all severe vaso-occlusive pain events in individuals living with sickle cell disease. In this study, stems cells are collected from the patient, modified in a lab, and then the gene-modified cells are given back to the patient. Participants must be between 13 and 40 years old. The study is taking place at sickle cell and transplant centers in California, Georgia, Illinois, Massachusetts, and Wisconsin.

Are you or your child at least 13 years old and have sickle cell disease? Do you or your child have sickle cell disease or beta-thalassemia? Researchers are testing whether a new antibody therapy prior to stem cell transplantation improves the success of the stem cell transplant in individuals at high risk for complications. Participants must be 13 years old or older. The study is taking place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Patients who have the stem cell transplant must live within 1 hour of the NIH Clinical Center for 3 months after the transplant.
The stem cells for the transplant come from a fully matched donor, 4 years old or older. Donors may provide blood samples for research.